Autofluorescence (LIFE/Onco-LIFE) examination should not be performed in persons for whom white-light bronchoscopy is contraindicated. Examples include persons with a known bleeding disorder or who are on anticoagulant therapy; persons with uncontrolled hypertension defined as systolic blood pressure > 200 mm Hg or diastolic pressure > 120 mm Hg; persons with unstable angina; those with a white blood cell count < 2,000 cells/µL or > 20,000 cells/µL; or a platelet count < 50,000/mm3.

Fluorescence examination is also contraindicated for persons who have recently received agents or treatments that could affect fluorescence signal or safety: chemo-preventive drugs (for example, retinoic acid) within 3 months, systemic cytotoxic chemotherapy within 6 months, fluorescent photosensitizing agents (hematoporphyrin derivatives) within 3 months, or ionizing radiation to the chest within 6 months.

The policy notes that several emerging lung imaging technologies remain investigational pending definitive clinical research. Xenon Xe-129 hyperpolarized-gas MRI has shown promising physiologic measures associated with disease progression in preliminary studies but is described as still awaiting definitive clinical research to establish clinical benefit; multiple active clinical trials are ongoing.

Software-assisted pulmonary tissue ventilation analysis (XV LVAS) and image-analysis workflows (including 4D dynamic-ventilation CT with color-map software) have demonstrated promising diagnostic performance in small pilot studies for pleural invasion and localized pleural adhesion, but evidence is limited by small sample sizes and requires validation in larger studies before routine clinical use can be recommended.

This Clinical Policy Bulletin is provided to assist in the administration of plan benefits and does not constitute an offer of coverage or medical advice. It contains only a partial, general description of plan or program benefits and is not a contract. Coverage determinations are governed by applicable plan or program provisions, and treating providers remain solely responsible for medical advice and member treatment. The bulletin may be updated and is subject to change.

Point laser Raman spectroscopy (LRS) and other adjunctive optical techniques have shown encouraging preliminary performance when added to white-light bronchoscopy plus autofluorescence bronchoscopy in small studies (for example, high sensitivity and specificity for detection of pre-neoplastic lesions in pilot work). However, these findings are preliminary and require validation in well-designed prospective trials before routine clinical adoption. Consequently, use of point LRS and similar adjuncts is characterized as investigational in this bulletin.

The evidence is insufficient to establish the clinical value of XV LVAS pulmonary tissue ventilation analysis and of software-assisted dynamic-ventilation CT (color-map/movie approaches) for routine care. Although small studies reported high sensitivity and specificity for specific applications (pleural invasion or localized pleural adhesion), these studies are limited by small cohorts, methodological constraints, and the need for further validation. Therefore, clinical value for these techniques is not established.

When indications are not consistent with the medical necessity section of this bulletin, LIFE/autofluorescence bronchoscopy and related adjunct techniques are considered not covered. The policy specifically characterizes technologies such as XV LVAS and other investigational modalities as lacking sufficient evidence for covered use when outside the listed medically necessary indications.

The bulletin describes several modalities as investigational or awaiting definitive research and therefore not recommended for routine clinical use for indications outside the medical necessity criteria. Providers billing for these investigational techniques may expect denials when plan provisions are not met.

Small, preliminary case series of software-assisted dynamic-ventilation CT and XV LVAS report promising diagnostic metrics but are explicitly characterized as preliminary. These modalities remain investigational and are not established as standard of care for lung imaging indications in this bulletin.

Adjunct optical techniques such as point laser Raman spectroscopy combined with bronchoscopy have produced high sensitivity and specificity in pilot studies, but the policy treats these as investigational pending confirmatory trials and does not list them as covered indications.

In the absence of explicit 'not covered' listings for every modality in the excerpt, the document characterizes multiple techniques as investigational when effectiveness has not been established. Providers should treat such techniques as investigational/not covered for indications not meeting the medical necessity criteria and should consult plan provisions for final coverage decisions.

Autofluorescence bronchoscopy systems (marketed as LIFE/Onco-LIFE) use blue excitation light transmitted via a flexible fiberoptic bronchoscope to elicit tissue autofluorescence and to enhance contrast between normal bronchial mucosa and dysplastic or carcinomatous tissue. Clinical studies (Onco-LIFE) have demonstrated that adding autofluorescence to white-light bronchoscopy increases detection rates of intra-epithelial neoplasia and early invasive carcinoma versus white-light alone, and quantitative fluorescence-reflectance metrics (for example, a threshold of >= 0.40) have been associated with improved sensitivity and specificity for detecting moderate/severe dysplasia, carcinoma in situ, and micro-invasive cancer. LIFE is intended for use as an adjunct to white-light bronchoscopy and should be used by operators trained in device techniques.